DOCSLIB.ORG

Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature CONTINUING MEDICAL EDUCATION Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature Amy Y-Y Chen, MD; Matthew J. Zirwas, MD RELEASE DATE: April 2009 TERMINATION DATE: April 2010 The estimated time to complete this activity is 1 hour. GOAL To understand steroid-induced rosacealike dermatitis (SIRD) to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Explain the clinical features of SIRD, including the 3 subtypes. 2. Evaluate the multifactorial pathogenesis of SIRD. 3. Recognize the importance of a detailed patient history and physical examination to diagnose SIRD. INTENDED AUDIENCE This CME activity is designed for dermatologists and generalists. CME Test and Instructions on page 195. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. March 2009. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 Credit TM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Dr. Chen owns stock in Merck & Co, Inc. Dr. Zirwas is a consultant for Coria Laboratories, Ltd, and is on the speakers bureau for Astellas Pharma, Inc, and Coria Laboratories, Ltd. These relationships are not relevant to this article. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Steroid-induced rosacealike dermatitis (SIRD) Accepted for publication March 6, 2008. Dr. Chen was a transitional intern, MetroWest Medical Center– is an eruption composed of papules, pustules, Framingham Union Hospital, Massachusetts. She currently is a fel- papulovesicles, and sometimes nodules with tel- low in dermatology clinical research, Department of Dermatology, angiectatic vessels on a diffuse erythematous and Wright State University Boonshoft School of Medicine, Dayton, edematous background. It results from prolonged Ohio. Dr. Zirwas is Assistant Professor, Division of Dermatology, topical steroid use or as a rebound phenomenon The Ohio State University School of Medicine, Columbus. Correspondence: Amy Y-Y Chen, MD, 1 Elizabeth Pl, Suite 200, after discontinuation of topical steroid. There are Dayton, OH 45408 ([email protected]). 3 types of SIRD that are classified based on the 198 CUTIS® Steroid-Induced Rosacealike Dermatitis location of the eruption: perioral, centrofacial, presentation, the patient used betamethasone valer- and diffuse. Diagnosis of this disease entity ate ointment daily. Five days prior to presentation, relies on a thorough patient history and physical he ran out of betamethasone valerate. The rash examination. Treatment involves discontinuation began to appear the day after the steroid was stopped of the offending topical steroid and administra- and progressively worsened on a daily basis. tion of oral and/or topical antibiotics. Topical Based on the patient’s history and physical calcineurin antagonists should be considered as examination, steroid-induced rosacealike derma- alternative or adjunctive therapies for patients titis (SIRD) was diagnosed. The patient was who do not respond to traditional treatments. counseled on the expected course of the disease. Dermatologists may need to provide psychologi- Treatment was initiated with doxycycline 100 mg cal support during office visits for patients who twice daily, clindamycin phosphate lotion 1% once have difficulty dealing with the discontinuation of daily, and tacrolimus ointment 0.1% once daily. On topical steroid and/or the psychological impact of follow-up a month later, the eruption had decreased RELEASE DATE: April 2009 a flare. Epidemiology, pathogenesis, histopathol- in intensity by approximately 50%. TERMINATION DATE: April 2010 ogy, and differential diagnosis of the entity also The estimated time to complete this activity is 1 hour. are reviewed. Comment Cutis. 2009;83:198-204. The development of topical corticosteroids in GOAL the 1950s opened new doors for dermatologists To understand steroid-induced rosacealike dermatitis (SIRD) to better manage patients with Case Report previously faced with treating intractable dermatoses. the condition A 42-year-old man previously not seen by a der- Since then and with the introduction of high-potency LEARNING OBJECTIVES matologist contacted our office for an emergent corticosteroids in the 1970s, a new dermatosis related Upon completion of this activity, dermatologists and general practitioners should be able to: appointment. The patient reported having an to the application of topical steroids to facial skin, excruciating facial eruption of several days’ dura- given several different names, has been described in 1. Explain the clinical features of SIRD, including the 3 subtypes. tion that his primary care physician was concerned the dermatology literature. As Weber1 reported, the 2. Evaluate the multifactorial pathogenesis of SIRD. might have been a serious infection. Because of the first cases of rosacealike dermatitis in the United States, 3. Recognize the importance of a detailed patient history and physical examination to urgency of his presentation, the patient underwent Great Britain, Scandinavia, and West Germany each diagnose SIRD. immediate evaluation. appeared years after the first publication on the clini- INTENDED AUDIENCE On examination, there was diffuse background cal use of steroids in the respective countries. The 2 This CME activity is designed for dermatologists and generalists. erythema on the chin, cheeks, and forehead with first case was reported in 1957. Frumess and Lewis superimposed erythematous papules and pinpoint described a dermatosis of unknown etiology that CME Test and Instructions on page 195. pustules (Figure). On further questioning, it was resembled seborrheic dermatitis, which they named discovered that the patient had been prescribed a light-sensitive seborrheid. In 1964, the term perioral topical steroid for a facial rash more than a year dermatitis was coined by Mihan and Ayres.3 Sneddon4 ago. The steroid initially worked well, but stron- used the term rosacealike dermatitis in 1969 because ger formulations had been necessary to progres- the eruption resembled rosacea, a well-established sively control the eruption. In the month prior to entity. Leyden et al5 named the disease steroid rosacea Diffuse background erythema on the forehead with superimposed erythematous papules. VOLUME 83, APRIL 2009 199 Steroid-Induced Rosacealike Dermatitis in 1974. In 1976, the term steroid dermatitis resembling The diffuse type affects the entire face, forehead, rosacea was introduced.6 Numerous other terms have and neck.9 been used to describe this disease entity including but Pathogenesis—The pathogenesis of SIRD and not limited to rosacealike eruption from topical steroid its rebound phenomenon is multifactorial but can and steroid-induced rosacealike dermatitis. We prefer the be partially explained by several hypotheses. After latter because it not only indicates the morphology of prolonged application of a topical steroid, functional the lesions but also points out their relationship with and anatomic cutaneous changes begin to occur. topical steroids. Steroid-induced rosacealike dermatitis has been Epidemiology—Steroid-induced rosacealike der- described as an intolerance reaction of seborrheic matitis results from repeated application of a topical skin to topically applied steroids. The seborrheic steroid to the face. The duration of use necessary to type of skin seems to be an essential factor because produce SIRD can vary from days to several years. in some experimental studies, application of potent Two months is the average, but 6 months or more of steroids to healthy skin rich in sebaceous glands has application is common.6-9 Although it was believed resulted in typical rosacealike symptoms.1,5,9,20,21 that only high-potency topical steroids could pro- Topical steroids may inhibit collagen synthesis, duce SIRD, it is important to note that topical leading to dermal atrophy. The decrease in support- hydrocortisone 1% also can cause such an eruption ing connective tissue allows for the passive dilation after prolonged use.8 of blood vessels and easier visualization of dermal The exact incidence of SIRD is not known, but capillaries that clinically manifest as prominent tel- it is believed to affect women more than men. The angiectases and background erythema.22,23 most common age at presentation is 40 to 50 years1,9; The immunosuppressive effects of topical steroids however, it also has been described in infants, chil- may facilitate the overgrowth of various bacteria, dren, and elderly patients.10-17 Despite its morpho- yeast, Demodex mites, or other microorganisms in logic resemblance to rosacea, SIRD
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Fucidin H Cream Patient Leaflet
    Scale Get-up Material No Sent by e-maiL l 100% GB 059516-XX Subject Date Date INS 175 x 280 mm 02/04/19 Colour Sign. Sign. Black RBE Preparation Place of production 213 Strength ® Packsize Fucidin H cream Ireland Comments: Page 1 of 2 Pharmacode 213 Font size: Heading: 9 pt, section: 8 pt, linespacing: 3 mm Mock-up for reg. purpose 175 mm IIE007-01 - 175 x 280 mm 175 x 280m Insert 100% PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin® H cream Fusidic acid and hydrocortisone acetate m Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. 20/01/2004 11/06/2018 IIE007-01 What is in this leaflet: Other medicines and Fucidin H cream 213 1. What Fucidin® H cream is and what it is used for Tell your doctor or pharmacist if you are taking, or have 2. Before you use Fucidin® H cream recently taken or might take any other medicines. 3. How to use Fucidin® H cream 4. Possible side effects Pregnancy and breast-feeding 5.
    [Show full text]
  • General Dermatology an Atlas of Diagnosis and Management 2007
    An Atlas of Diagnosis and Management GENERAL DERMATOLOGY John SC English, FRCP Department of Dermatology Queen's Medical Centre Nottingham University Hospitals NHS Trust Nottingham, UK CLINICAL PUBLISHING OXFORD Clinical Publishing An imprint of Atlas Medical Publishing Ltd Oxford Centre for Innovation Mill Street, Oxford OX2 0JX, UK tel: +44 1865 811116 fax: +44 1865 251550 email: [email protected] web: www.clinicalpublishing.co.uk Distributed in USA and Canada by: Clinical Publishing 30 Amberwood Parkway Ashland OH 44805 USA tel: 800-247-6553 (toll free within US and Canada) fax: 419-281-6883 email: [email protected] Distributed in UK and Rest of World by: Marston Book Services Ltd PO Box 269 Abingdon Oxon OX14 4YN UK tel: +44 1235 465500 fax: +44 1235 465555 email: [email protected] © Atlas Medical Publishing Ltd 2007 First published 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. A catalogue record of this book is available from the British Library ISBN-13 978 1 904392 76 7 Electronic ISBN 978 1 84692 568 9 The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations.
    [Show full text]
  • Acute-Onset Alopecia
    PHOTO CHALLENGE Acute-Onset Alopecia Justin P. Bandino, MD; Dirk M. Elston, MD A previously healthy 45-year-old man presented to the dermatology department with abrupt onset of patchy, progressively worsening alopecia of the scalp as well as nausea with emesis and blurry vision of a few weeks’ duration. All symptoms were temporally associated with a new demoli- tion job the patient had started at an industrial site. He reportedcopy 10 other contractors were simi- larly affected. The patient denied paresthesia or other skin changes. On physical examination, large patches of smooth alopecia without ery- thema,not scale, scarring, tenderness, or edema that coalesced to involve the majority of the scalp, eye- brows, and eyelashes (inset) were noted. Do WHAT’S THE DIAGNOSIS? a. alopecia areata b. dioxin-induced alopecia c. phosgene-induced alopecia d. syphilitic alopecia CUTIS e. thallium-induced alopecia PLEASE TURN TO PAGE E25 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]). E24 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2019. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Thallium-Induced Alopecia t the time of presentation, a punch biopsy speci- pencil point–shaped fractures that shed approximately men of the scalp revealed nonscarring alopecia 1 to 2 months after injury. The 10% of scalp hairs in A with increased catagen hairs; follicular minia- the resting telogen phase have no matrix and thus are turization; peribulbar lymphoid infiltrates; and fibrous unaffected.
    [Show full text]
  • Designing a Campaign on Topical Steroids Misuse
    Ministry Of Higher Education University Of Al-Qadysiah And Scientific Research College Of Pharmacy Designing a Campaign On Topical steroids misuse By: Hussein A. Abdulwahab Ali H. Abd Zaid Supervised By: Dr. Hussein A. Sahib 1 بسمميحرلا نمحرلا هللا ۞ َوقُ ْم َر ِّة ِز ْدَِي ِع ْه ًًب ۞ صدق هللا العظيم 2 List of subjects : Dedication 4 Aim 4 Chapter one : introduction 5 Potency 8 Adverse effects 10 Study on topical steroids 18 Chapter tow : methodology 19 Chapter three : 22 Conclusion discussion recommendations References 25 3 Dedication : We dedicate this work to our families and to the Iraqi army Aim : Is to make a campaign that raise awareness on topical steroids’ misuse and side effects 4 Chapter One Introduction 5 1.1 Introduction 1.1.1 Corticosteroids: Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Two main classes of corticosteroids, glucocorticoids and mineralocorticoids , are involved in a wide range of physiologic processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior.[1] Some common naturally occurring steroid hormones are cortisol (C21H30O5), corticosterone (C21H30O4), cortisone (C21H28O5) and aldosterone (C21H28O5). (Note that aldosterone and cortisone share the same chemical formula but the structures are different.) The main corticosteroids produced by the adrenal cortex are cortisol and aldosterone. [2] 1.1.2 Topical steroids: The introduction of topical corticosteroids (TC) by Sulzberger and Witten in 1952 is considered to be the most significant landmark in the history of therapy of dermatological disorders.[3] This historical event was gradually, followed by the introduction of a large number of newer TC molecules of varying potency rendering the therapy of various inflammatory cutaneous disorders more effective and less time consuming.
    [Show full text]
  • Dovobet Gel Patient Information Leaflet
    L Scale Get-up Material No Sent by e-maiL l Scale Get-up Material No Sent by e-mail 100% Used for: GB 000000-XXComments: Insert, 2 columns Page 1 IIE015-02Subject Daivobet®, Dovobet®, Xamiol ® Date gel. SpaceDate for text: 2 X 67,5 x 580 mm. Subject Date Date INS 160 x 600 mm 05/05/20 Colour Sign. MaterialSign. number must be printed on both sides Colour Sign. Sign. 160 x 600 mm 08/09/2010 JUG Black RBE Material number on page 1, OCRB 8pt kerning+10(Quark)/ Preparation 100% 08/06/2018 OMA Place of productionOCRB MEDIUM 8pt kerning+50(Indesign) Preparation Place of production Strength ® Strength Packsize Dovobet gel Ireland Packsize Ireland Comments: Comments: Page 1 of 2 Font size: 9 pt Mock-up for reg. purpose 160 mm IIE015-02 - 160 x 600 mm - Page 1 of 2 2. 05/05/20 Package leaflet: Information for the user Dovobet® 50 micrograms/g + 0.5 mg/g gel RBE calcipotriol/betamethasone SOP_00867 SOP_003993 and SOP_000647, SOP_000962 Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. 6 • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
    [Show full text]
  • PSORCON® E Emollient Ointment (Diflorasone Diacetate Ointment) 0.05%
    PSORCON® E Emollient Ointment (diflorasone diacetate ointment) 0.05% For Topical Use Not For Ophthalmic Use DESCRIPTION Each gram of Psorcon E Emollient Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is: 6α,9-difluoro-11β,17,21-trihydroxy- 16β-methyl-pregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is represented below: Psorcon E Emollient Ointment contains diflorasone diacetate in an emollient, occlusive base consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, 1 occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and are then excreted by the kidneys.
    [Show full text]
  • Pathological Investigation of Rosacea with Particular Regard Of
    CORE Metadata, citation and similar papers at core.ac.uk Provided by White Rose E-theses Online A Clinico-Pathological Investigation of Rosacea with Particular Regard to Systemic Diseases Dr. Mustafa Hassan Marai Submitted in accordance with the requirements for the degree of Doctor of Medicine The University of Leeds School of Medicine May 2015 “I can confirm that the work submitted is my own and that appropriate credit has been given where reference has been made to the work of others” “This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement” May 2015 The University of Leeds Dr. Mustafa Hassan Marai “The right of Dr Mustafa Hassan Marai to be identified as Author of this work has been asserted by him in accordance with the Copyright, Designs and Patents Act 1988” Acknowledgement Firstly, I would like to thank all the patients who participate in my rosacea study, giving their time and providing me with all of the important information about their disease. This is helped me to collect all of my study data which resulted in my important outcome of my study. Secondly, I would like to thank my supervisor Dr Mark Goodfield, consultant Dermatologist, for his continuous support and help through out my research study. His flexibility, understanding and his quick response to my enquiries always helped me to relive my stress and give me more strength to solve the difficulties during my research. Also, I would like to thank Dr Elizabeth Hensor, Data Analyst at Leeds Institute of Molecular Medicine, Section of Musculoskeletal Medicine, University of Leeds for her understanding the purpose of my study and her help in analysing my study data.
    [Show full text]
  • Dermatology Dr Matt Smialowski GP, Tunbridge Wells Introduction
    Dermatology Dr Matt Smialowski GP, Tunbridge Wells Introduction . Overview of General Practice Dermatology . Based on curriculum matrix . Images from dermnet.nz . Management from dermnet.nz and NICE CKS . Focus on the common presenting complaints and overview of treatments . Quiz and Questions Dermatology Vocabulary . Useful to be able to describe the problem in notes / referrals . Configuration . Nummular / discoid: round or coin-shaped . Linear: often occurs due external factors (scratching) . Target: concentric rings . Annular: lesions grouped in a circle. Serpiginous: snake like . Reticulate: net-like with spaces Dermatology Vocabulary . Morphology . Macule: small area of skin 5-10mm, altered colour, not elevated . Patch: larger area of colour change, with smooth surface . Papule: elevated, solid, palpable <1cm diameter . Nodule: elevated, solid, palpable >1cm diameter . Cyst: papule or nodule that contains fluid / semi-fluid material . Plaque: circumscribed, palpable lesion >1cm diameter . Vesicle: small blister <1cm diameter that contains liquid . Pustule: circumscribed lesion containing pus (not always infected) . Bulla: Large blister >1cm diameter that contains fluid . Weal: transient elevation of the skin due to dermal oedema Skin Function . Prevention of water loss . Immune defence . Protection against UV damage . Temperature regulation . Synthesis of vitamin D . Sensation . Aesthetics Skin Structure Eczematous Eruptions Cheilitis / Peri-oral Dermatitis . Common problem . Acute / relapsing / recurrent . Causes . Chelitis . Environmental: sun damage . Inflammatory . Angular cheilits . Infection: fungal . Vitamin B / iron deficiency . Perioral dermatitis . Potent topical steroids Pompholyx . Vesicular form of hand or foot eczema. Commonly affects young adults. Causes . Sweating . Irritants . Recurrent crops of itchy deep-seated blisters. Pompholyx . General Measures . Cold packs . Soothing emollients . Gloves / avoid allergens . Prescription: . Potent topical steroids . Oral steroids .
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Folliculitis-It's More Than Acne!
    Paul K. Shitabata, M.D. Dermatopathology Institute Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 SAPHO Syndrome Synovitis Acne Pustulosis Hyperostosis Osteitis Thursday, May 23, 13 Acne Conglobata Severe form of acne characterized by burrowing and interconnecting abscesses and irregular scars Chest, shoulders, back, buttocks, upper arms, thighs, and face Sudden deterioration of existing active papular or pustular acne Recrudescence of quiescent acne Thursday, May 23, 13 Chloracne Toxic chemicals exposure (dioxins) Few months after swallowing, inhaling or touching Occupational exposure, enviromental poisoning Ukrainian President Victor Yushchenko Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Histopathology Folliculitis with varying degrees of the following depending upon the stage and temporal progression Telangiectasia Sebaceous hyperplasia Fibrosis Granulomas Thursday, May 23, 13 Disease Associaons of Acne Rosacea Steroid rosacea HIV-1 Pyoderma faciale Perioral dermatitis Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Histopathology Hair shaft infiltrated by fungal yeast and hyphae May have epidermal involvement Suspect with acute suppurative folliculitis Woods lamp negative PAS/GMS to confirm T. tonsurans most common Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May 23, 13 Thursday, May
    [Show full text]
  • Common Dermatological Conditions
    Produced: 13/01/2017 Common Dermatological Conditions Dr Alvin Chong Senior Lecturer Dr Catherine Scarff Senior Lecturer Dr Laura Scardamaglia Clinical Senior Lecturer Produced: 13/01/2017 Learning objectives: Describe the common features of • Eczema variants and psoriasis • Acne and rosacea • Scabies • Understand the principles of investigation and treatment for common dermatological problems Produced: 13/01/2017 Case: A 22 year old student presents with 3 months of worsening rash. Not responding to 1% hydrocortisone cream. Produced: 13/01/2017 Erythematous, ill defined, scaly, patches in flexures Produced: 13/01/2017 Diagnosis: Atopic eczema Produced: 13/01/2017 Atopic Eczema • Genetic predisposition Clinical features (Family history) • Itchy ++ • Atopic triad • Erythematous - Asthma • Diffuse - Hayfever • Flexural- thinnest skin - Eczema • Worse in winter (dry) • Worse in summer (heat) Produced: 13/01/2017 Atopic Eczema Model Genetic Predisposition Environmental -Filaggrin mutation- Triggers Leads to reduced barrier •Irritants (soaps etc) function •Allergy •Heat •Infection (Staph.) •“Itch-scratch cycle” •Stress and anxiety 1. Palmer et al Nat. Genet. 38,441-6 Eczema Produced: 13/01/2017 Atopic eczema in an infant Produced: 13/01/2017 3 year old girl, eczema since infancy Produced: 13/01/2017 35 year old man with longstanding eczema mainly of the flexures. Produced: 13/01/2017 Lichenification: The result of chronic rubbing and scratching Produced: 13/01/2017 Eczema Variants Produced: 13/01/2017 Discoid Eczema • Eczema in annular disc
    [Show full text]